Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?: Pro:
- 31 December 1998
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (13) , 1993-1995
- https://doi.org/10.1016/s0959-8049(98)00309-8
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Treatment of Non-Small Cell Lung Cancer with Ifosfamide (IFO) + 4’-Epiadriamycin (EPI) + Platinum vs. IFO + EPI: A GETLAC StudyOncology, 1995
- Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group ResultsJNCI Journal of the National Cancer Institute, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapyCancer, 1992
- A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1991
- A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.Journal of Clinical Oncology, 1990
- Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancerBritish Journal of Cancer, 1989
- Cisplatin Dose Intensity in Non-Small Cell Lung Cancer: Phase II Results of a Day 1 and Day 8 High-Dose RegimenJNCI Journal of the National Cancer Institute, 1989
- Chemotherapy for Bronchogenic CarcinomaJAMA, 1977